194 related articles for article (PubMed ID: 10023676)
1. Correlation between the status of the p53 gene and survival in patients with stage I non-small cell lung carcinoma.
Tomizawa Y; Kohno T; Fujita T; Kiyama M; Saito R; Noguchi M; Matsuno Y; Hirohashi S; Yamaguchi N; Nakajima T; Yokota J
Oncogene; 1999 Jan; 18(4):1007-14. PubMed ID: 10023676
[TBL] [Abstract][Full Text] [Related]
2. p53 null mutations undetected by immunohistochemical staining predict a poor outcome with early-stage non-small cell lung carcinomas.
Hashimoto T; Tokuchi Y; Hayashi M; Kobayashi Y; Nishida K; Hayashi S; Ishikawa Y; Tsuchiya S; Nakagawa K; Hayashi J; Tsuchiya E
Cancer Res; 1999 Nov; 59(21):5572-7. PubMed ID: 10554037
[TBL] [Abstract][Full Text] [Related]
3. p53 mutations in defined structural and functional domains are related to poor clinical outcome in non-small cell lung cancer patients.
Skaug V; Ryberg D; Kure EH; Arab MO; Stangeland L; Myking AO; Haugen A
Clin Cancer Res; 2000 Mar; 6(3):1031-7. PubMed ID: 10741731
[TBL] [Abstract][Full Text] [Related]
4. Mutations in exon 7 and 8 of p53 as poor prognostic factors in patients with non-small cell lung cancer.
Huang C; Taki T; Adachi M; Konishi T; Higashiyama M; Miyake M
Oncogene; 1998 May; 16(19):2469-77. PubMed ID: 9627113
[TBL] [Abstract][Full Text] [Related]
5. High frequency of deletion mutations in p53 gene from squamous cell lung cancer patients in Taiwan.
Wang YC; Chen CY; Chen SK; Cherng SH; Ho WL; Lee H
Cancer Res; 1998 Jan; 58(2):328-33. PubMed ID: 9443413
[TBL] [Abstract][Full Text] [Related]
6. Prognostic significance of allelic imbalances on chromosome 9p in stage I non-small cell lung carcinoma.
Tomizawa Y; Adachi J; Kohno T; Hamada K; Saito R; Noguchi M; Matsuno Y; Hirohashi S; Yamaguchi N; Yokota J
Clin Cancer Res; 1999 May; 5(5):1139-46. PubMed ID: 10353749
[TBL] [Abstract][Full Text] [Related]
7. TP53 mutational pattern in Spanish and Polish non-small cell lung cancer patients: null mutations are associated with poor prognosis.
de Anta JM; Jassem E; Rosell R; Martínez-Roca M; Jassem J; Martínez-López E; Monzó M; Sánchez-Hernández JJ; Moreno I; Sánchez-Céspedes M
Oncogene; 1997 Dec; 15(24):2951-8. PubMed ID: 9416838
[TBL] [Abstract][Full Text] [Related]
8. p53 alterations in non-small cell lung cancers correlate with metastatic involvement of hilar and mediastinal lymph nodes.
Marchetti A; Buttitta F; Merlo G; Diella F; Pellegrini S; Pepe S; Macchiarini P; Chella A; Angeletti CA; Callahan R
Cancer Res; 1993 Jun; 53(12):2846-51. PubMed ID: 8389245
[TBL] [Abstract][Full Text] [Related]
9. p53 gene mutations are associated with shortened survival in patients with advanced non-small cell lung cancer: an analysis of medically managed patients.
Murakami I; Hiyama K; Ishioka S; Yamakido M; Kasagi F; Yokosaki Y
Clin Cancer Res; 2000 Feb; 6(2):526-30. PubMed ID: 10690534
[TBL] [Abstract][Full Text] [Related]
10. The utility of p53 immunostaining of transbronchial biopsy specimens of lung cancer: p53 overexpression predicts poor prognosis and chemoresistance in advanced non-small cell lung cancer.
Kawasaki M; Nakanishi Y; Kuwano K; Yatsunami J; Takayama K; Hara N
Clin Cancer Res; 1997 Jul; 3(7):1195-200. PubMed ID: 9815799
[TBL] [Abstract][Full Text] [Related]
11. Tumor expression of S100A6 correlates with survival of patients with stage I non-small-cell lung cancer.
De Petris L; Orre LM; Kanter L; Pernemalm M; Koyi H; Lewensohn R; Lehtiö J
Lung Cancer; 2009 Mar; 63(3):410-7. PubMed ID: 18620780
[TBL] [Abstract][Full Text] [Related]
12. P53 and K-ras mutations are frequent events in microscopically negative surgical margins from patients with nonsmall cell lung carcinoma.
Jassem J; Jassem E; Jakóbkiewicz-Banecka J; Rzyman W; Badzio A; Dziadziuszko R; Kobierska-Gulida G; Szymanowska A; Skrzypski M; Zylicz M
Cancer; 2004 May; 100(9):1951-60. PubMed ID: 15112277
[TBL] [Abstract][Full Text] [Related]
13. Deregulated expression of c-mos in non-small cell lung carcinomas: relationship with p53 status, genomic instability, and tumor kinetics.
Gorgoulis VG; Zacharatos P; Mariatos G; Liloglou T; Kokotas S; Kastrinakis N; Kotsinas A; Athanasiou A; Foukas P; Zoumpourlis V; Kletsas D; Ikonomopoulos J; Asimacopoulos PJ; Kittas C; Field JK
Cancer Res; 2001 Jan; 61(2):538-49. PubMed ID: 11212247
[TBL] [Abstract][Full Text] [Related]
14. A novel molecular staging protocol for non-small cell lung cancer.
Miyake M; Adachi M; Huang C; Higashiyama M; Kodama K; Taki T
Oncogene; 1999 Apr; 18(14):2397-404. PubMed ID: 10327061
[TBL] [Abstract][Full Text] [Related]
15. Clinical significance of p53 in non-small-cell lung cancer.
Komiya T; Hirashima T; Kawase I
Oncol Rep; 1999; 6(1):19-28. PubMed ID: 9864395
[TBL] [Abstract][Full Text] [Related]
16. Prognostic significance of cyclin D1 and retinoblastoma expression in combination with p53 abnormalities in primary, resected non-small cell lung cancers.
Nishio M; Koshikawa T; Yatabe Y; Kuroishi T; Suyama M; Nagatake M; Sugiura T; Ariyoshi Y; Mitsudomi T; Takahashi T
Clin Cancer Res; 1997 Jul; 3(7):1051-8. PubMed ID: 9815783
[TBL] [Abstract][Full Text] [Related]
17. Prognostic implications of molecular and immunohistochemical profiles of the Rb and p53 cell cycle regulatory pathways in primary non-small cell lung carcinoma.
Burke L; Flieder DB; Guinee DG; Brambilla E; Freedman AN; Bennett WP; Jones RT; Borkowski A; Caporaso NA; Fleming M; Trastek V; Pairolero P; Tazelaar H; Midthun D; Jett JR; Liotta LA; Travis WD; Harris CC
Clin Cancer Res; 2005 Jan; 11(1):232-41. PubMed ID: 15671551
[TBL] [Abstract][Full Text] [Related]
18. p53 gene mutations in non-small-cell lung cancer cell lines and their correlation with the presence of ras mutations and clinical features.
Mitsudomi T; Steinberg SM; Nau MM; Carbone D; D'Amico D; Bodner S; Oie HK; Linnoila RI; Mulshine JL; Minna JD
Oncogene; 1992 Jan; 7(1):171-80. PubMed ID: 1311061
[TBL] [Abstract][Full Text] [Related]
19. p53 mutations in lung tumors: relationship to putative susceptibility markers for cancer.
Ryberg D; Kure E; Lystad S; Skaug V; Stangeland L; Mercy I; Børresen AL; Haugen A
Cancer Res; 1994 Mar; 54(6):1551-5. PubMed ID: 8137262
[TBL] [Abstract][Full Text] [Related]
20. Multiple molecular marker testing (p53, C-Ki-ras, c-erbB-2) improves estimation of prognosis in potentially curative resected non-small cell lung cancer.
Schneider PM; Praeuer HW; Stoeltzing O; Boehm J; Manning J; Metzger R; Fink U; Wegerer S; Hoelscher AH; Roth JA
Br J Cancer; 2000 Aug; 83(4):473-9. PubMed ID: 10945494
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
